The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma

被引:94
|
作者
Azuhata, T
Scott, D
Takamizawa, S
Wen, J
Davidoff, A
Fukuzawa, M
Sandler, A
机构
[1] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA
[2] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[3] Nihon Univ, Sch Med, Tokyo, Japan
关键词
survivin; apoptosis; neuroblastoma; cell death; tumor necrosis factor-related apoptosis-inducing ligand;
D O I
10.1053/jpsu.2001.28839
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background/Purpose:Apoptotic factors inducing or preventing cell death may intrinsically govern the behavior of some tumors. Survivin is a recently described member of the inhibitor of apoptosis protein (IAP) family, that is expressed in a cell cycle-dependent manner and is found in tumors of unfavorable histology. This study examines the presence of several apoptotic factors, including survivin, in neuroblastoma (NB) tumors. Clues to survivin's function in NB are provided by examining its association with behavior and cell dynamics in tumors and cell lines. Methods: Expression of a panel of apoptosis factors were quantified in 15 NB and related tumors before chemotherapy and in 3 NB cell lines (NB7, NB10, and NB16). Survivin and other apoptotic factors, as well N-myc amplification in primary tumors was correlated with recurrent disease and outcome. Proliferation rate, apoptosis assays, cell cycle analysis, and drug- or immune-mediated cell death were assessed in cell lines and evaluated in the context of differential survivin and apoptosis gene expression. Results: All 7 tumors that went on to recur expressed survivin, whereas expression was absent in all 8 tumors that went into remission. N-myc was amplified in 4 (57.1%) of the 7 recurrent tumors. Of the 8 tumors that were cured, Fas was expressed in 3 (38%), TRAIL-R1 in 6 (76%) and tumor necrosis factor (TNF)-R1 in 8 (100%), whereas these pro-apoptotic receptors were present in only 1 (14%), 1 (14%), and 4 (57%) of the 7 tumors that went on to recur, respectively. Of the 3 cell lines, NB10 expressed the least survivin, displayed the lowest proliferation index, and had the fewest number of cells in the G2/M (mitotic) phase of the cell cycle. Furthermore, NB10 also was most sensitive to TNF-related apoptosis-inducing ligand (TRAIL) or etoposide-induced cell death. Conclusions: In primary NB tumors, survivin expression was associated with tumors of high risk and unfavorable prognosis, whereas pro-apoptotic receptor expression was more abundant in tumors of favorable prognosis. In this small series, survivin expression appeared to be more predictive of recurrent disease than N-myc amplification. In cell lines, survivin expression was cell cycle dependent, and its expression was associated with greater proliferation rates and greater resistance to drug- or immune-mediated cell death. Survivin expression may become a useful prognostic marker in NB and could be a potential target for the treatment of this tumor. Copyright (C) 2001 by W.B. Saunders Company.
引用
收藏
页码:1785 / 1791
页数:7
相关论文
共 50 条
  • [21] ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo
    Yu, Yang
    Zhao, Yanling
    Choi, Jongmin
    Shi, Zhongcheng
    Guo, Linjie
    Elizarraras, John
    Gu, Andy
    Cheng, Feng
    Pei, Yanxin
    Lu, Dai
    Fabbri, Muller
    Agarwal, Saurabh
    Zhang, Chunchao
    Jung, Sung Yun
    Foster, Jennifer H.
    Yang, Jianhua
    CANCERS, 2022, 14 (22)
  • [22] Neuroblastoma-derived secretory protein messenger RNA levels correlate with high-risk neuroblastoma
    Vasudevan, Sanjeev A.
    Russell, Heidi V.
    Okcu, M. Fatih
    Burlingame, Susan M.
    Liu, Zhiyun J.
    Yang, Jianhua
    Nuchtern, Jed G.
    JOURNAL OF PEDIATRIC SURGERY, 2007, 42 (01) : 148 - 152
  • [23] Surgical challenges associated with intensive treatment protocols for high-risk neuroblastoma
    Cantos, Mae F.
    Gerstle, J. Ted
    Irwin, Meredith S.
    Pappo, Alberto
    Farley, Shannon
    Cheang, Timothy
    Kim, Peter C. W.
    JOURNAL OF PEDIATRIC SURGERY, 2006, 41 (05) : 960 - 965
  • [24] Dinutuximab: A Review in High-Risk Neuroblastoma
    Sheridan M. Hoy
    Targeted Oncology, 2016, 11 : 247 - 253
  • [25] Retinoid therapy of high-risk neuroblastoma
    Reynolds, CP
    Matthay, KK
    Villablanca, JG
    Maurer, BJ
    CANCER LETTERS, 2003, 197 (1-2) : 185 - 192
  • [26] Influence of Sarcopenia in High-risk Neuroblastoma
    Kawakubo, Naonori
    Souzaki, Ryota
    Koga, Yuuki
    Kinoshita, Yoshiaki
    Ohga, Shouichi
    Taguchi, Tomoaki
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S43 - S43
  • [27] The transcriptome landscape of high-risk neuroblastoma
    Wei, Jun S.
    Zhang, Shile
    Song, Young K.
    Asgharzadeh, Shahab
    Sindiri, Sivasish
    Wen, Xinyu
    Patidar, Rajesh
    Auvil, Jaime M. Guidry
    Gerhard, Daniela S.
    Seeger, Robert
    Maris, John M.
    Khan, Javed
    CANCER RESEARCH, 2016, 76
  • [28] High-Risk Neuroblastoma: A Surgical Perspective
    Jacobson, Jillian C.
    Clark, Rachael A.
    Chung, Dai H.
    CHILDREN-BASEL, 2023, 10 (02):
  • [29] Mouse models of high-risk neuroblastoma
    Alvin Kamili
    Caroline Atkinson
    Toby N. Trahair
    Jamie I. Fletcher
    Cancer and Metastasis Reviews, 2020, 39 : 261 - 274
  • [30] HIGH-RISK NEUROBLASTOMA: A Therapy in Evolution
    Fong, Abraham
    Park, Julie R.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2009, 26 (08) : 539 - 548